Which has higher earnings and valuation, GRCE or IMUX?

Immunic is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A Immunic N/A N/A -$97.17M -$4.38 N/A

Is GRCE or IMUX more profitable?

Grace Therapeutics' return on equity of -36.11% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Immunic N/A -157.89% -107.88%

Do analysts prefer GRCE or MENS?

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 169.06%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Grace Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, GRCE or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is GRCE or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Jyong Biotech N/A N/A N/A

Is MIST or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Grace Therapeutics N/A -36.11% -34.39%

Grace Therapeutics (GRCE) Competitors

$2.23 -0.06 (-2.62%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.23 0.00 (0.00%)

As of 09/15/2026 07:30 PM Eastern

Compare

GRCE vs. IMUX, MENS, LFCR, MIST, and NRXP

Should you buy Grace Therapeutics stock or one of its competitors? Grace Therapeutics's main competitors and comparable companies include Immunic (IMUX), Jyong Biotech (MENS), Lifecore Biomedical (LFCR), Milestone Pharmaceuticals (MIST), and NRx Pharmaceuticals (NRXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Grace Therapeutics compare to Immunic?

Grace Therapeutics (NASDAQ:GRCE) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Grace Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Immunic has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, Immunic had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 11 mentions for Immunic and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat Immunic's score of 0.53 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Very Positive
Immunic	Positive

Immunic is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Grace Therapeutics' return on equity of -36.11% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Immunic	N/A	-157.89%	-107.88%

Grace Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 169.06%. Immunic has a consensus target price of $47.25, suggesting a potential upside of 355.64%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Grace Therapeutics and Immunic tied by winning 7 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to Jyong Biotech?

Grace Therapeutics (NASDAQ:GRCE) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

6.1% of Grace Therapeutics shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Jyong Biotech	N/A	N/A	N/A

Grace Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market.

In the previous week, Grace Therapeutics and Grace Therapeutics both had 1 articles in the media. Grace Therapeutics' average media sentiment score of 1.91 beat Jyong Biotech's score of 1.89 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Very Positive
Jyong Biotech	Very Positive

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 169.06%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Grace Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Grace Therapeutics beats Jyong Biotech on 6 of the 10 factors compared between the two stocks.

How does Grace Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Lifecore Biomedical presently has a consensus price target of $6.50, suggesting a potential upside of 57.00%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 169.06%. Given Grace Therapeutics' higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Grace Therapeutics	N/A	-36.11%	-34.39%

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Grace Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.22	-$40.50M	-$1.07	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

In the previous week, Lifecore Biomedical had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 2 mentions for Lifecore Biomedical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat Lifecore Biomedical's score of 1.04 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lifecore Biomedical	Positive
Grace Therapeutics	Very Positive

Summary

Lifecore Biomedical beats Grace Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 1 articles in the media. Grace Therapeutics' average media sentiment score of 1.91 beat Milestone Pharmaceuticals' score of 1.87 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Very Positive
Grace Therapeutics	Very Positive

Grace Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	74.52	-$63.06M	-$0.69	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Milestone Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 589.88%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 169.06%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics' return on equity of -36.11% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Grace Therapeutics	N/A	-36.11%	-34.39%

Summary

Milestone Pharmaceuticals beats Grace Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Grace Therapeutics has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	119.69	-$28.62M	-$0.55	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

NRx Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 914.71%. Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 169.06%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, NRx Pharmaceuticals had 12 more articles in the media than Grace Therapeutics. MarketBeat recorded 13 mentions for NRx Pharmaceuticals and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat NRx Pharmaceuticals' score of 0.82 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Positive
Grace Therapeutics	Very Positive

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Grace Therapeutics has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Grace Therapeutics	N/A	-36.11%	-34.39%

Summary

NRx Pharmaceuticals beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$48.17M	$12.42B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.57%	12.21%
P/E Ratio	-1.89	789.61	272.90	25.31
Price / Sales	N/A	953.16	723.41	107.94
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	0.56	10.41	10.44	6.18
Net Income	-$7.79M	$2.83B	$3.49B	$357.96M
7 Day Performance	4.21%	-1.51%	-0.75%	-0.56%
1 Month Performance	3.24%	0.80%	-0.38%	-3.62%
1 Year Performance	-27.83%	3.92%	18.95%	6.05%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	2.1171 of 5 stars	$2.23 -2.6%	$6.00 +169.1%	-27.4%	$48.17M	N/A	N/A	N/A
IMUX Immunic	2.9487 of 5 stars	$13.11 +2.7%	$47.25 +260.4%	+34.1%	$174.10M	N/A	N/A	70
MENS Jyong Biotech	N/A	$2.39 +5.3%	N/A	-95.9%	$172.58M	N/A	N/A	31	Positive News
LFCR Lifecore Biomedical	1.5534 of 5 stars	$4.40 +1.1%	$6.50 +47.7%	-46.1%	$164.66M	$128.87M	N/A	690	High Trading Volume
MIST Milestone Pharmaceuticals	2.7934 of 5 stars	$1.20 -0.8%	$6.40 +433.3%	-52.9%	$150.64M	$1.55M	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. IMUX, MENS, LFCR, MIST, and NRXP

How does Grace Therapeutics compare to Immunic?

Summary

How does Grace Therapeutics compare to Jyong Biotech?

Summary

How does Grace Therapeutics compare to Lifecore Biomedical?

Summary

How does Grace Therapeutics compare to Milestone Pharmaceuticals?

Summary

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. IMUX, MENS, LFCR, MIST, and NRXP

How does Grace Therapeutics compare to Immunic?

Which has more risk & volatility, GRCE or IMUX?

Does the media prefer GRCE or IMUX?

Which has higher earnings and valuation, GRCE or IMUX?

Is GRCE or IMUX more profitable?

Do analysts rate GRCE or IMUX?

Do insiders & institutionals hold more shares of GRCE or IMUX?

Summary

How does Grace Therapeutics compare to Jyong Biotech?

Do institutionals and insiders have more ownership in GRCE or MENS?

Which has higher earnings & valuation, GRCE or MENS?

Is GRCE or MENS more profitable?

Which has more volatility and risk, GRCE or MENS?

Does the media refer more to GRCE or MENS?

Do analysts prefer GRCE or MENS?

Summary

How does Grace Therapeutics compare to Lifecore Biomedical?

Which has more risk & volatility, LFCR or GRCE?

Do analysts rate LFCR or GRCE?

Is LFCR or GRCE more profitable?

Do insiders & institutionals hold more shares of LFCR or GRCE?

Which has higher earnings & valuation, LFCR or GRCE?

Does the media favor LFCR or GRCE?

Summary

How does Grace Therapeutics compare to Milestone Pharmaceuticals?

Does the media refer more to MIST or GRCE?

Which has stronger earnings and valuation, MIST or GRCE?

Which has more risk and volatility, MIST or GRCE?

Do institutionals and insiders hold more shares of MIST or GRCE?

Do analysts rate MIST or GRCE?

Is MIST or GRCE more profitable?

Summary

How does Grace Therapeutics compare to NRx Pharmaceuticals?

Which has preferable valuation and earnings, NRXP or GRCE?

Which has more risk and volatility, NRXP or GRCE?

Do analysts recommend NRXP or GRCE?

Does the media prefer NRXP or GRCE?

Do institutionals and insiders have more ownership in NRXP or GRCE?

Is NRXP or GRCE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools